Moll UM - Search Results

1

p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.

Slade N, Moll UM, Brdar B, Zorić A, Jelaković B. Slade N, et al. Among authors: moll um. Mutat Res. 2009 Apr 26;663(1-2):1-6. doi: 10.1016/j.mrfmmm.2009.01.005. Epub 2009 Feb 4. Mutat Res. 2009. PMID: 19428366 Free PMC article. Review.

2

Aristolochic acid and the etiology of endemic (Balkan) nephropathy.

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. Grollman AP, et al. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12129-34. doi: 10.1073/pnas.0701248104. Epub 2007 Jul 9. Proc Natl Acad Sci U S A. 2007. PMID: 17620607 Free PMC article.

3

Mutational analysis of p53 in human tumors: immunocytochemistry.

Slade N, Moll UM. Slade N, et al. Among authors: moll um. Methods Mol Biol. 2003;234:231-43. doi: 10.1385/1-59259-408-5:231. Methods Mol Biol. 2003. PMID: 12824536

4

p63 and p73: roles in development and tumor formation.

Moll UM, Slade N. Moll UM, et al. Mol Cancer Res. 2004 Jul;2(7):371-86. Mol Cancer Res. 2004. PMID: 15280445 Review.

5

Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.

Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Concin N, et al. Among authors: moll um. Cancer Res. 2004 Apr 1;64(7):2449-60. doi: 10.1158/0008-5472.can-03-1060. Cancer Res. 2004. PMID: 15059898

6

Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCP.

Erster S, Slade N, Moll UM. Erster S, et al. Among authors: moll um. Methods Mol Biol. 2003;234:219-30. doi: 10.1385/1-59259-408-5:219. Methods Mol Biol. 2003. PMID: 12824535

7

The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.

Hofstetter G, Berger A, Berger R, Zorić A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R, Concin N. Hofstetter G, et al. Int J Gynecol Cancer. 2012 Mar;22(3):372-9. doi: 10.1097/IGC.0b013e31823ca031. Int J Gynecol Cancer. 2012. PMID: 22246403

8

DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.

Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. Zaika AI, et al. Among authors: moll um. J Exp Med. 2002 Sep 16;196(6):765-80. doi: 10.1084/jem.20020179. J Exp Med. 2002. PMID: 12235210 Free PMC article.

9

Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.

Becker K, Pancoska P, Concin N, Vanden Heuvel K, Slade N, Fischer M, Chalas E, Moll UM. Becker K, et al. Among authors: moll um. Int J Oncol. 2006 Oct;29(4):889-902. Int J Oncol. 2006. PMID: 16964385

10

DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation.

Slade N, Zaika AI, Erster S, Moll UM. Slade N, et al. Among authors: moll um. Cell Death Differ. 2004 Mar;11(3):357-60. doi: 10.1038/sj.cdd.4401335. Cell Death Differ. 2004. PMID: 14685155 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters